Regarding the issue of children born through gene editing, members of the summit conclude that: “it would be irresponsible to proceed with any clinical use… unless and until (i) the relevant safety and efficacy issues have been resolved… and (ii) there is broad societal consensus about the appropriateness of the proposed application" (National Academies, 2015).